TLDR Folliculitis decalvans is a rare skin disease causing hair loss and requires personalized treatment.
Folliculitis decalvans (FD) was described as an uncommon, chronic skin disease leading to cicatricial alopecia and follicular pustules, predominantly affecting men and rarely children. The etiopathogenesis indicated an immunologic response to staphylococcal superantigens might contribute to FD. Treatment needed to be tailored to the clinical form and severity of the condition.
1 citations,
September 2019 in “Practica medicală” Hair loss is linked to heart disease and metabolic syndrome, and while current treatments vary in effectiveness, more research is needed for better solutions.
40 citations,
March 2019 in “Journal of the American Academy of Dermatology” Clindamycin and rifampicin are the most effective treatments for folliculitis decalvans, but more research is needed.
254 citations,
January 2004 in “Journal of the American Academy of Dermatology” Accurate diagnosis and aggressive treatment are crucial to prevent permanent hair loss in cicatricial alopecia.
5 citations,
June 2021 in “JAAD Case Reports” Platelet-rich plasma therapy may help treat folliculitis decalvans but benefits might not last without ongoing treatment.
27 citations,
January 2015 in “Current problems in dermatology” The document concludes that primary scarring alopecias cause permanent hair loss, have unpredictable outcomes, and lack definitive treatments, requiring personalized care.
